基于围术期血流动力学开展心脏代谢共病病人术后谵妄的研究

注册号:

Registration number:

ChiCTR2600126726 

最近更新日期:

Date of Last Refreshed on:

2026-06-15 10:24:51 

注册时间:

Date of Registration:

2026-06-15 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于围术期血流动力学开展心脏代谢共病病人术后谵妄的研究

Public title:

Study on Postoperative Delirium in Patients with Cardiometabolic Multimorbidity Based on Perioperative Hemodynamics

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于围术期血流动力学开展心脏代谢共病病人术后谵妄的研究

Scientific title:

Study on Postoperative Delirium in Patients with Cardiometabolic Multimorbidity Based on Perioperative Hemodynamics

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

段晓霞 

研究负责人:

段晓霞 

Applicant:

Duan Xiaoxia 

Study leader:

Duan Xiaoxia 

申请注册联系人电话:

Applicant telephone:

+86 13568635458

研究负责人电话:

Study leader's
telephone:

+86 13568635458

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

782348971@qq.com

研究负责人电子邮件:

Study leader's E-mail:

782348971@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

四川省泸州市江阳区太平街25号西南医科大学附属医院

研究负责人通讯地址:

四川省泸州市江阳区太平街25号

Applicant address:

25 Taiping Street, Jiangyang District, Luzhou, Sichuan

Study leader's address:

25 Taiping Street, Jiangyang District, Luzhou, Sichuan

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

西南医科大学附属医院

Applicant's institution:

The Affiliated Hospital of Southwest Medical University

研究负责人所在单位:

西南医科大学附属医院

Affiliation of the Leader:

The Affiliated Hospital of Southwest Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KY2026337

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

西南医科大学附属医院临床试验伦理委员会

Name of the ethic committee:

The Clinical Research Ethics Committee Affiliated Hospital of Southwest Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2026-05-23 00:00:00

伦理委员会联系人:

张增瑞

Contact Name of the ethic committee:

Zhang Zengrui

伦理委员会联系地址:

四川省泸州市江阳区太平街25号

Contact Address of the ethic committee:

25 Taiping Street, Jiangyang District, Luzhou, Sichuan

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 830 3165273

伦理委员会联系人邮箱:

Contact email of the ethic committee:

274692738@qq.com

研究实施负责(组长)单位:

西南医科大学附属医院

Primary sponsor:

The Affiliated Hospital of Southwest Medical University

研究实施负责(组长)单位地址:

四川省泸州市江阳区太平街25号

Primary sponsor's address:

25 Taiping Street, Jiangyang District, Luzhou, Sichuan

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川省

市(区县):

Country:

China

Province:

Sichuan

City:

单位(医院):

西南医科大学附属医院

具体地址:

四川省泸州市江阳区太平街25号

Institution
hospital:

The Affiliated Hospital of Southwest Medical University

Address:

25 Taiping Street, Jiangyang District, Luzhou, Sichuan

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

Self raised

研究疾病:

术后谵妄, 心脏代谢共病  

Target disease:

Postoperative delirium (POD), Cardiometabolic Multimorbidity

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

析因分组(即根据危险因素或暴露因素分组) 

Study design:

Factorial 

研究目的:

1. 验证术前心脏代谢共病(CMM)状态增加术后谵妄(POD)的发病率; 2. 探讨CMM病人POD发生率增加的风险因素; 3. 分析不同疾病组合的CMM状态POD的发生率及严重程度的差异; 4. 基于围术期临床特征构建POD的预测模型。  

Objectives of Study:

1. To verify that preoperative CMM status increases the incidence of POD; 2. To explore the risk factors for increased POD incidence in patients with CMM; 3. To analyze differences in the incidence and severity of POD among different disease combinations in patients with CMM status; 4. To develop a predictive model for POD based on perioperativ.e clinical characteristics.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.无法配合完成检测量表者; 2.滥用药物或精神药物; 3.研究期间二次手术; 4.存在严重呼吸功能、肝肾功能不全者。

Exclusion criteria:

1.Patients unable to cooperate in completing the assessment scales; 2.Substance abuse or psychotropic drug abuse; 3.Undergoing a second surgery during the study period; 4.Presence of severe respiratory dysfunction, or significant hepatic or renal insufficiency.

研究实施时间:

Study execute time:

From 2026-06-16 00:00:00 To 2029-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-06-16 00:00:00 To 2028-06-30 00:00:00

干预措施:

Interventions:

组别:

未患心脏代谢共病组

样本量:

4481

Group:

Group without cardiometabolic multimorbidity

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

患心脏代谢共病组

样本量:

1494

Group:

Group with cardiometabolic multimorbidity

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川省 

市(区县):

 

Country:

China

Province:

Sichuan

City:

单位(医院):

西南医科大学附属医院 

单位级别:

三级甲等 

Institution
hospital:

The Affiliated Hospital of Southwest Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

四川省 

市(区县):

 

Country:

China

Province:

Sichuan

City:

单位(医院):

自贡市第一人民医院 

单位级别:

三级甲等 

Institution
hospital:

Zigong First People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

四川省 

市(区县):

 

Country:

China

Province:

Sichuan

City:

单位(医院):

西南医科大学附属医院 

单位级别:

三级甲等 

Institution
hospital:

The Affiliated Hospital of Southwest Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

四川省 

市(区县):

 

Country:

China

Province:

Sichuan

City:

单位(医院):

合江县人民医院 

单位级别:

三级乙等 

Institution
hospital:

Hejiang County People's Hospital

Level of the institution:

Tertiary B

国家:

中国

省(直辖市):

四川省 

市(区县):

 

Country:

China

Province:

Sichuan

City:

单位(医院):

简阳市人民医院 

单位级别:

三级甲等 

Institution
hospital:

Jianyang City People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

术后全因死亡率

指标类型:

次要指标

Outcome:

Postoperative all-cause mortality

Type:

Secondary indicator

测量时间点:

出院后一年内

测量方法:

电话随访

Measure time point of outcome:

Within one year after discharge

Measure method:

Telephone follow-up

指标中文名:

主要不良心脑血管事件

指标类型:

次要指标

Outcome:

Major adverse cardiac and cerebrovascular events

Type:

Secondary indicator

测量时间点:

术后30天内

测量方法:

电子病历诊断记录

Measure time point of outcome:

Within 30 days after surgery

Measure method:

Electronic medical record diagnosis documentation

指标中文名:

住院天数

指标类型:

次要指标

Outcome:

Length of hospital stay (LOS)

Type:

Secondary indicator

测量时间点:

患者出院后

测量方法:

电子病历

Measure time point of outcome:

Post-discharge

Measure method:

Electronic medical record

指标中文名:

术后谵妄(POD)

指标类型:

主要指标

Outcome:

Postoperative delirium

Type:

Primary indicator

测量时间点:

术后1、2、3天

测量方法:

3D-CAM量表(3分钟谵妄评估量表)

Measure time point of outcome:

1, 2, 3 days after surgery

Measure method:

the 3-Minute Diagnostic Interview for Confusion Assessment Method,3D-CAM

指标中文名:

术后住院期间其它并发症

指标类型:

次要指标

Outcome:

Postoperative in-hospital other complications

Type:

Secondary indicator

测量时间点:

患者出院后

测量方法:

电子病历

Measure time point of outcome:

Post-discharge

Measure method:

Electronic medical record

指标中文名:

远期认知功能

指标类型:

次要指标

Outcome:

Long-term cognitive function

Type:

Secondary indicator

测量时间点:

出院后一年内

测量方法:

认知功能电话问卷

Measure time point of outcome:

Within one year after discharge

Measure method:

Telephone Interview for cognitive Status-modified, TICS-m

指标中文名:

术后谵妄严重程度

指标类型:

次要指标

Outcome:

Severity of postoperative delirium

Type:

Secondary indicator

测量时间点:

术后1、2、3天

测量方法:

3D-CAM-S量表(测量严重程度)

Measure time point of outcome:

1, 2, 3 days after surgery

Measure method:

3-Minute Diagnostic Interview for Confusion Assessment Method-defined Delirium Severity scoring method

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

采集:通过医院电子病历系统或当面、电话询问患者获得原始数据; 管理:根据研究方案设计统一的CRF,用于记录患者的基本信息、临床特征、围术期指标及随访结局等。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Collection: Raw data were obtained from the hospital's electronic medical record system, or through face-to-face or telephone interviews with patients; Management: A standardized Case Record Form (CRF) was designed according to the study protocol to document patients' demographic information, clinical characteristics, perioperative parameters, and follow-up outcomes.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2026-06-15 10:24:14